FDA Gives First Approval To Non-Opioid Treatment For Withdrawal

May 17, 2018
FDA on Wednesday (May 16) approved US WorldMeds LLC’s Lucemyra, the first agency-approved non-opioid treatment for mitigating the symptoms of opioid withdrawal. Lucemyra, FDA noted, is only approved for treatment up to 14 days and is to be used as part of a broader, long-term treatment plan for managing opioid use disorder. The agency also is requiring 15 additional postmarketing studies to assess longer-term use and use in children and newborns. Thus far, patients with OUD have managed withdrawal by...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.